NASDAQ · ANGO
AngioDynamics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for ANGO has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Nov 2026 | $-0.09 | $-0.08 | $-0.11 | 2 |
| Feb 2027 | $-0.08 | $-0.05 | $-0.10 | 2 |
| May 2027 | $-0.02 | $-0.02 | $-0.02 | 2 |
| Aug 2027 | $-0.08 | $-0.06 | $-0.09 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · MarketBeat · RTTNews- Zacks · Oct 9, 9:58 AM EDTANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/YAngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
- The Motley Fool · Oct 8, 10:43 PM EDTAngioDynamics (ANGO) Q1 2027 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- The Motley Fool · Oct 8, 11:11 AM EDTWhy AngioDynamics Crashed TodayAngioDynamics beat on both top and bottom lines this morning.
- MarketBeat · Oct 8, 10:02 AM EDTAngioDynamics Q1 Earnings Call HighlightsAngioDynamics (NASDAQ:ANGO) reported fiscal 2027 first-quarter revenue growth of 6.9% to $80.9 million, led by continued expansion in its Med Tech segment, while the company maintained its full-year outlook and announced that Eric Honroth will become president and chief executive
- RTTNews · Oct 8, 7:36 AM EDTAngioDynamics Reiterates FY27 Outlook; Appoints Eric Honroth President And CEO – Update(RTTNews) – While reporting financial results for the first quarter on Thursday, medical technology company AngioDynamics, Inc. (ANGO) reiterated its adjusted loss and net sales guidance for the full year 2027, based on its first quarter performance and current outlook for the re
- RTTNews · Oct 8, 6:40 AM EDTAngioDynamics Names Honroth As CEO, Clemmer To Retire; Stock Down In Premarket(RTTNews) – Medical technology company, AngioDynamics, Inc. (ANGO) on Thursday announced the appointment of Eric Honroth as President and Chief Executive Officer (CEO) and a member of its Board of Directors, effective November 2, 2026.
- Zacks · Oct 8, 6:15 AM EDTAngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue EstimatesAngioDynamics (ANGO) delivered earnings and revenue surprises of +60.00% and -0.03%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Oct 8, 6:12 AM EDTAngioDynamics Inc. Q1 Loss Declines(RTTNews) – AngioDynamics Inc. (ANGO) announced Loss for first quarter of -$7.10 million
- NASDAQ.com · Oct 7, 4:00 PM EDTPre-Market Earnings Report for October 8, 2026 : PEP, NG, ANGO, HELE, TLRY, BYRNThe following companies are expected to report earnings prior to market open on 10/08/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Pepsico, Inc. (PEP)is reporting for the quarter ending September 30, 2026. The beverages company's consensus earn
- RTTNews · Oct 2, 6:50 AM EDTAngioDynamics Names Jacobi Hospital As ALPHA-PE Research Fund Recipient(RTTNews) – AngioDynamics, Inc. (ANGO), a medical technology company focused on vascular and cancer treatment technologies, announced that Jacobi Hospital in New York has been selected as an ALPHA-PE Research Fund award recipient.
- Zacks · Aug 13, 11:30 AM EDTAngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- MarketBeat · Aug 11, 7:04 PM EDTAngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027AngioDynamics (NASDAQ:ANGO) expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Can
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for AngioDynamics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.